puc-header

11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma

53 Pages Posted: 5 May 2020 Publication Status: Review Complete

See all articles by Joachim Siaw

Joachim Siaw

University of Gothenburg - Department of Medical Biochemistry and Cell Biology

Niloufar Javanmardi

University of Gothenburg - Department of Laboratory Medicine

Jimmy Van den Eynden

Ghent University - Department Human Structure & Repair

Dan Emil Lind

University of Gothenburg - Department of Medical Biochemistry and Cell Biology

Susanne Fransson

University of Gothenburg - Department of Laboratory Medicine

Angela Marinez-Monleon

University of Gothenburg - Department of Laboratory Medicine

Anna Djos

University of Gothenburg - Department of Laboratory Medicine

Rose-Marie Sjöberg

University of Gothenburg - Department of Laboratory Medicine

Malin Östensson

University of Gothenburg

Helena Carén

University of Gothenburg

Gunhild Trøen

University of Oslo - Institute of Clinical Medicine

Klaus Beiske

University of Oslo - Institute of Clinical Medicine

Ana Bergegall

University of Valencia

Rosa Noguera

University of Valencia

Wei-Yun Lai

University of Gothenburg - Department of Medical Biochemistry and Cell Biology

Per Kogner

Karolinska Institutet

Ruth H. Palmer

University of Gothenburg - Department of Medical Biochemistry and Cell Biology

Bengt Hallberg

University of Gothenburg - Institute of Biomedicine

Tommy Martinsson

University of Gothenburg - Department of Laboratory Medicine

More...

Abstract

High-risk 11q deleted neuroblastomas typically display undifferentiated/poorly differentiated morphology. Neuroblastoma is thought to develop from Schwann cell precursors and undifferentiated neural crest (NC) derived cells. It is therefore vital to understand mechanisms involved in the block of differentiation. We identify an important role for oncogenic ALK-ERK1/2-SP1 signaling in maintenance of undifferentiated NC-derived progenitors via repression of DLG2, a tumor suppressor in neuroblastoma. DLG2 is expressed in the ‘bridge signature’ that represents the transcriptional transition state when neural crest cells or Schwann Cell Precursors become chromaffin cells of the adrenal gland. We show that restoration of DLG2 expression spontaneously drives neuroblastoma differentiation highlighting the importance of DLG2 in this process. Further, genetic analysis of high-risk 11q-deletion neuroblastomas identified genetic lesions in the DLG2 gene. Our data also suggest that further exploration of other ‘bridge genes’ may help elucidate the mechanisms underlying the differentiation of NC-derived progenitors and their contribution to neuroblastoma.

Keywords: ALK, neuroblastoma, DLG2, tumor suppressor, retinoic acid, ERK, TRK, NGF, SNP, genomic profiles, whole genome sequencing.

Suggested Citation

Siaw, Joachim and Javanmardi, Niloufar and Van den Eynden, Jimmy and Lind, Dan Emil and Fransson, Susanne and Marinez-Monleon, Angela and Djos, Anna and Sjöberg, Rose-Marie and Östensson, Malin and Carén, Helena and Trøen, Gunhild and Beiske, Klaus and Bergegall, Ana and Noguera, Rosa and Lai, Wei-Yun and Kogner, Per and Palmer, Ruth H. and Hallberg, Bengt and Martinsson, Tommy, 11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. Available at SSRN: https://ssrn.com/abstract=3571291 or http://dx.doi.org/10.2139/ssrn.3571291
This version of the paper has not been formally peer reviewed.

Joachim Siaw

University of Gothenburg - Department of Medical Biochemistry and Cell Biology ( email )

Sweden

Niloufar Javanmardi

University of Gothenburg - Department of Laboratory Medicine ( email )

Sweden

Jimmy Van Den Eynden

Ghent University - Department Human Structure & Repair ( email )

Dan Emil Lind

University of Gothenburg - Department of Medical Biochemistry and Cell Biology

Sweden

Susanne Fransson

University of Gothenburg - Department of Laboratory Medicine

Sweden

Angela Marinez-Monleon

University of Gothenburg - Department of Laboratory Medicine

Sweden

Anna Djos

University of Gothenburg - Department of Laboratory Medicine

Sweden

Rose-Marie Sjöberg

University of Gothenburg - Department of Laboratory Medicine

Sweden

Malin Östensson

University of Gothenburg

Viktoriagatan 30
Göteborg, 405 30
Sweden

Helena Carén

University of Gothenburg

Viktoriagatan 30
Göteborg, 405 30
Sweden

Gunhild Trøen

University of Oslo - Institute of Clinical Medicine

Kirkeveien 166
Building 2H
Oslo, N-0450
Norway

Klaus Beiske

University of Oslo - Institute of Clinical Medicine

Kirkeveien 166
Building 2H
Oslo, N-0450
Norway

Ana Bergegall

University of Valencia

Avda. de los Naranjos s/n
Valencia, Valencia E-46022
Spain

Rosa Noguera

University of Valencia

Avda. de los Naranjos s/n
Valencia, Valencia E-46022
Spain

Wei-Yun Lai

University of Gothenburg - Department of Medical Biochemistry and Cell Biology

Sweden

Per Kogner

Karolinska Institutet

Granits väg 4
Section for Integrative Physiology
Solna, Stockholm 17171
Sweden

Ruth H. Palmer

University of Gothenburg - Department of Medical Biochemistry and Cell Biology

Sweden

Bengt Hallberg

University of Gothenburg - Institute of Biomedicine ( email )

Tommy Martinsson (Contact Author)

University of Gothenburg - Department of Laboratory Medicine ( email )

Sweden

Click here to go to Cell.com

Paper statistics

Downloads
42
Abstract Views
798
PlumX Metrics